Connect Pen | C-Pen | Instant translator | Compact and portable | Text to speech scanner

Product Information

Emma Wilmot, Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust said:“Integrating innovative technology as a routine part of diabetes care is an important step to improve diabetes care. If you are prescribed a Novo smart pen and wish to use it like a standard insulin pen without the connectivity function, then you can discuss this with your clinic or healthcare provider - for example, so you can see if a different pen may suit you better. How can smart insulin pens affect diabetes management? Surface Pen is an essential tool you should get for your Surface PCs since all Surface except Surface RT, Surface 2, and Surface Laptop Go models are compatible with Surface Pen. It works best on Surface Go, Surface Pro, Surface Laptop Studio, and Surface Studio.

Novo Nordisk has announced that the NovoPen® 6 and NovoPen Echo® Plus are both now available on prescription for individuals with diabetes who are treated with Novo Nordisk insulin in the UK. Currently, insulin injection dosing information is manually recorded in a logbook or app. However, in clinical practice, incomplete or inaccurate information on insulin dosing and timing can be a significant barrier to optimising glycaemic control. Xiaomi Pad 6 Pro uses a newer processor -25-30% better CPU performance & 40% better Gaming Performance. James Ridgeway, 34, is a diabetes specialist nurse (DSN) with type 1 diabetes who has seen both the personal and professional side of using smart insulin pens.

Talk to us about diabetes

The Surface Pen information should be listed under the “Mouse, keyboard, & pen” section. In this case, my Surface Pen is already connected with 85% battery left. Smart insulin pens are reusable devices that automatically record when a person has injected insulin, including how much has been injected and at what time of the day. There are a few approaches to pairing or connecting Surface Pen to your PC and here is the most straightforward way to do that.

Based on the findings of the targeted literature review, an initial questionnaire including DCE choice tasks was developed and tested through telephone interviews ( n=6 with T1D [ n=3 USA, n=3 UK]; n=14 with T2D [ n=7 USA, n=7 UK]) during which participants and interviewers viewed synchronized questionnaire content online. Objectives of the interviews were: (i) to understand patients’ perspectives on unique features of connected insulin pens; (ii) to assess if the candidate DCE attributes were relevant, tradeable, and understandable; and (iii) to test the adequacy of the attribute levels included in the DCE. To ensure that participant input could be adequately reflected, interviews were conducted in two rounds during which the interview guide, survey, and DCE were iteratively updated. Data (a transcribed dialogue) were analyzed with ATLAS.ti version 8 (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany) using a mixture of inductive “bottom-up” and deductive “top-down” approaches. The outcomes of the qualitative analysis from the qualitative interviews were summarized visually in a conceptual map showing the themes and subthemes that participants discussed (Online Resources 3 and 4) and were used to refine the DCE choice task format, update wording of attributes, levels, and other aspects of the questionnaire, and further clarify attribute levels and device descriptions. Comparable to other DCEs [ 32], 77.6% of participants passed the stability test and 87.4% passed the dominance test. A connected insulin pen was chosen over a non-connected pen in 80.3% of DCE tasks. The estimated model (Online Resource 6) was able to explain the choices that the participants made (adjusted McFadden R 2=0.390) and identified three opt-in behaviors: technology supporters (74.9%; n=405), who always chose a connected insulin pen; technology skeptics (8.8%; n=47), who only chose very competitive connected insulin pens (i.e., pens that include many desirable features); and technology opponents (16.3%; n=88), who never chose a connected insulin pen. Place your pen on an item and hold it there until the circle around the pointer completes. Then move the item to where you want it to go. Rest your hand on the screen, like you would on a piece of paper, then start writing. Your Surface is designed to ignore your hand and other inputs while you write. Use the pointer that appears under your pen tip to guide you while you ink. inch 2.8K ultra-clear eye protection screen, 144Hz 7-speed variable refresh rate, 16:10 aspect ratioAcceleration sensor, Gyroscope, Front and rear ambient light sensors, Hall sensor, Side fingerprint sensor

Turn Bluetooth on. If Surface Pen appears in the list of discovered devices, it may not be properly paired yet. So, select it from the list and remove the device. Once your pen is paired, you'll be able to use the top button. The top button does different things depending on how you interact with the button. To change these shortcuts, go to Start > Settings > Devices > Pen & Windows Ink . Providing your smartphone or tablet supports Near Field Communication (NFC) then Novo’s smart pens can be connected with the following apps: A random constant logit (RCL) model was developed and estimated within a random utility maximization framework [ 33– 36]. This model extended classical multinomial logit models for choice data to account for heterogeneity in participants’ tendency to opt into a connected pen [ 37]. The model assumed that the T1D and T2D populations are made up of separate groups of people who attach a different value (i.e., utility) to using a non-connected pen compared to a connected pen. Smaller utility associated with a non-connected pen indicated greater desirability of a connected pen. This opt-out behavior was represented by a finite mixture of utility values associated with the non-connected pen, making the RCL a specific case of latent class analysis [ 38]. The final model specification was selected by estimating the RCL with varying assumptions about the number of groups in the population and choosing the model with the lowest Bayesian information criterion.

The app to which the SmartPen or Smart Button can connect may also be able to record blood sugar values. If this feature is available, the app may require the blood sugar data to be entered manually after taking a measurement or receive data automatically from a Bluetooth ®-enabled glucose monitoring system (e.g., blood glucose meter, continuous glucose monitor, and/or flash glucose monitor). These blood sugar entries can then be integrated into the dosing logbook where the information can be presented as figures and charts. Additionally, reminders may be set to remind users to test their blood sugar. If glucose reading is not available in the app, a paper diary (UK)/paper logbook (USA) or a separate app that cannot receive data from the SmartPen or Smart Button may be used. Subgroup-specific RAI scores were obtained based on age (18–44/45–64/≥65 years), diabetes type (T1D/T2D), country of residence (USA/UK), and insulin regimen (bolus only/basal only/basal + bolus). Likelihood ratio tests were used to test if accounting for subgroups improved the ability of the RCL to explain choices made in the DCE.